Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) target price upped to $92.00, reported earlier today by FBR & Co.
- Updated: September 15, 2016
Just yesterday Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded 0.22% higher at $129.70. The company’s 50-day average is $131.16 and its two hundred day average is $136.34. With the last stock price close down 4.87% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. Trade volume was was down over the average, with 1,577,865 shares of ALXN changing hands under the typical 1,839,270 shares..
Stating a possible downside of -0.29%, FBR & Co. raised the estimated target of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to $92
See Chart Below:
A total of 18 firms have issued a ratings update on Alexion Pharmaceuticals Inc.. Seven firms rate the company a strong buy, six firms rate the stock a buy, seven analyts rate the company a hold, 0 rate the stock to underperform, and finally 0 analystsrate the company as sell with a 12-month target of $187.61
Alexion Pharmaceuticals Inc. has a price-earnings of 326 with a one-year low of $110.56 and a one-year high of $193.45 and has a total market value of $0.0.
More About Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), and a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.